Vanda Pharmaceuticals Inc. (VNDA) is on the cusp of key regulatory milestones that have the potential to drive significant growth and expand its therapeutic footprint in 2026 and beyond.This global biopharmaceutical company currently markets three approved therapies - Fanapt, Hetlioz, and Ponvory - and has two drug candidates awaiting FDA approval for their first indications.Fanapt, an antipsychot...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.